Back
Esperion Therapeutics Quote, Financials, Valuation and Earnings
Sponsored
ESPR
Sponsored
Invest. Do Good. Get Rewarded. Just $0.26/Share!
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
54
ESPR
Esperion Therapeutics
Last Price:
2.53
Seasonality Move:
33.73%
7 Day Trial
ALL ACCESS PASS
$
7
Trade on Tuesday. Profit on Friday. Rinse & Repeat
Get the full details now.Esperion Therapeutics Price Quote
$2.53
+0.01 (+2.43%)
(Updated: November 23, 2024 at 5:34 AM ET)
Esperion Therapeutics Key Stats
Buy
54
Esperion Therapeutics (ESPR)
is a Buy
Day range:
$2.45 - $2.54
52-week range:
$1.16 - $3.40
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
1.46
P/B ratio:
0%
Volume:
2.6M
Avg. volume:
4.4M
1-year change:
108.26%
Market cap:
$496.5M
Revenue:
$116.3M
EPS:
$-0.64
How Much Does Esperion Therapeutics Make?
-
How Much Are Esperion Therapeutics's Sales Annually?
ESPR Revenues are $116.3M -
How Much Profit Does Esperion Therapeutics's Make A Year?
ESPR net income is -$209.2M
Is Esperion Therapeutics Growing As A Company?
-
What Is Esperion Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.52% -
What Is Esperion Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Esperion Therapeutics Stock Price Performance
-
Did Esperion Therapeutics Stock Go Up Last Month?
Esperion Therapeutics share price went up by 18.31% last month -
Did ESPR's Share Price Rise Over The Last Year?
ESPR share price rose by 108.26% over the past 1 year
What Is Esperion Therapeutics 52-Week High & Low?
-
What Is Esperion Therapeutics’s 52-Week High Share Price?
Esperion Therapeutics has traded as high as $3.40 over the past 52 weeks -
What Is Esperion Therapeutics’s 52-Week Low Share Price?
Esperion Therapeutics has traded as low as $1.16 over the past 52 weeks
Esperion Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Esperion Therapeutics?
-
How Much Debt Does Esperion Therapeutics Have?
Total long term debt quarterly is $262.9M -
How Much Cash Does Esperion Therapeutics Have?
Cash and short term investments quarterly total is $144.7M -
What Is Esperion Therapeutics’s Book Value Per Share?
Book value per share is -1.89
Is Esperion Therapeutics Cash Flow Positive?
-
What Is ESPR Cash Flow From Operations?
Cash flow from operations (TTM) is -$25.8M -
What Is Esperion Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $56M -
What Is Esperion Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$317K
Esperion Therapeutics Return On Invested Capital
Data Unavailable
Esperion Therapeutics Earnings Date & Stock Price
-
What Is Esperion Therapeutics's Stock Price Today?
A single share of ESPR can be purchased today for 2.52 -
What Is Esperion Therapeutics’s Stock Symbol?
Esperion Therapeutics trades on the nasdaq under the ticker symbol: ESPR -
When Is Esperion Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Esperion Therapeutics is scheduled on February 27, 2025 -
When Is ESPR's next ex-dividend date?
Esperion Therapeutics's next ex-dividend date is November 25, 2024 -
How To Buy Esperion Therapeutics Stock?
You can buy Esperion Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Esperion Therapeutics Competitors
-
Who Are Esperion Therapeutics's Competitors?
Below is a list of companies who compete with Esperion Therapeutics or are related in some way:
Esperion Therapeutics Dividend Yield
-
What Is ESPR Dividend Yield?
Esperion Therapeutics’s dividend yield currently is 0% -
What Is Esperion Therapeutics’s Payout Ratio?
Esperion Therapeutics’s payout ratio is 0% -
When Did Esperion Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 25, 2024 -
What Is Esperion Therapeutics’s Dividend Per Share?
Esperion Therapeutics pays a dividend of $0.00 per share
Esperion Therapeutics Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | 13.91% |
Revenue: | 52% | -0.16% |
Analyst Recommendations
Buy Recommendations: | 2 |
---|---|
Hold Recommendations: | 1 |
Sell Recommendations: | 0 |
Price Target: | 7.51 |
Upside from Last Price: | 197.95% |